Piper Jaffray analyst Tyler Van Buren noted that the TNF step-through for Incyte (INCY) and Eli Lilly's (LLY) Olumiant potentially decreases the overall market opportunity, but he believes Olumiant will get some share of TNF failure patients given that Lilly announced it is pricing the drug "aggressively" at a potential 60% price discount to AbbVie's (ABBV) Humira. Van Buren estimates this price to be a potential 50% price discount to the other oral JAK approved for RA, Pfizer's (PFE) Xeljanz. The analyst keeps an Overweight rating on Incyte, citing the durable revenue base through the late 2020s that should come from Olumiant along with the "significant potential" he sees in its pipeline opportunities.